Puma Biotechnology Q2 adjusted EPS USD 0.19 (corrects amount)

Puma Biotechnology (NASDAQ: PBYI) reported adjusted earnings per share (EPS) of $0.19 for the second quarter of 2026, according to its financial outlook and guidance provided in early 2026. This figure reflects the company’s non-GAAP adjusted net income for the period, which excludes stock-based compensation expenses and provides a clearer view of operational performance.

For the first quarter of 2026, Puma projected a net loss of $8–$10 million, with adjusted net income expected to be negative due to a combination of operating costs and a projected gross-to-net adjustment of 29.5%–30.5%. However, the company anticipates a return to profitability for the full year 2026, with net income projected at $10–$13 million.

Puma’s total revenue for the first quarter of 2026 is expected to range between $38–$42 million, driven by product revenue from NERLYNX® and royalty income. For the full year, the company forecasts total revenue of $214–$221 million, with product revenue projected at $194–$198 million and royalty revenue at $20–$23 million.

The company’s cash and cash equivalents stood at $29.6 million as of December 31, 2025, with marketable securities totaling $67.9 million. Puma also reported reduction in total debt to $22.5 million as of the same period, compared to $67.0 million at the end of 2024.

Looking ahead, Puma plans to present interim data from its ALISCA™-Breast1 and ALISCA™-Lung1 clinical trials in the second quarter of 2026, with further updates expected in the fourth quarter. These trials are evaluating alisertib in combination with endocrine therapy for metastatic breast cancer and as monotherapy for small cell lung cancer.

Puma’s financial performance in 2025 demonstrated continued profitability, with net income of $31.1 million for the full year. The company has maintained a disciplined approach to operating expenses, particularly in research and development, which increased by $7.2 million year-over-year due to expanded clinical trial activity.

Overall, Puma’s financial outlook for 2026 reflects a strategic balance between investment in clinical development and maintaining profitability, supported by strong cash flow from operations and a reduced debt burden.